UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $264.12 Million Stake in Illumina, Inc. $ILMN

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 3.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,502,137 shares of the life sciences company’s stock after selling 61,102 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.99% of Illumina worth $264,121,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Illumina during the second quarter worth $3,374,423,000. Primecap Management Co. CA bought a new position in shares of Illumina in the second quarter valued at about $617,981,000. Jupiter Topco LLC acquired a new position in Illumina during the 2nd quarter worth about $358,652,000. WCM Investment Management LLC lifted its position in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Illumina during the 2nd quarter worth about $293,846,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $213.63 on Tuesday. The stock has a market capitalization of $32.26 billion, a P/E ratio of 39.86, a P/E/G ratio of 3.03 and a beta of 1.44. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $231.81. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The business has a 50-day moving average price of $195.10 and a two-hundred day moving average price of $156.54.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,799,688 shares of company stock worth $379,517,231 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ILMN shares. Piper Sandler restated an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Citigroup upped their target price on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Royal Bank Of Canada increased their price target on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Barclays boosted their price objective on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.